Russian Ministry of Health (2000): Approved Protocol for Medical Trials of Aires Matrix Applicator — BAP Treatment
Period: August 28 – November 17, 2000
Authorization: Commission on devices for rapid diagnostics, Committee on New Medical Equipment, Russian Federation Ministry of Public Health (Protocol #3, July 14, 2000)
Device: Aires Matrix Applicator prototypes — self-adhesive film (26.4×26.4 mm) with graphical pattern of lines ≤0.1 mm width, applied to biologically active points (BAPs) and zones (BAZs)
Units tested: 500 applicator prototypes
Device Description
The Aires Matrix Applicator (Russian Patent #7007) is a self-adhesive polyester film bearing a high-symmetry graphical pattern. The pattern consists of graphite lines ≤0.1 mm width arranged in a specific topological structure. The applicator is placed on biologically active points and zones of the body surface.
The therapeutic mechanism described: passive correction of the weak electromagnetic radiation emitted in the area of active points and zones, normalized through the biophysical action of the fractal pattern. This approach is based on the AIRES fractal geometry principles — the same underlying physics that inform the modern Lifetune resonator products — applied to point-specific bioelectromagnetic correction rather than ambient field transformation.
Regulatory Approval Process
The clinical trials were instituted following:
- Expert commission authorization: Protocol #3, Committee on New Medical Equipment, Ministry of Public Health (July 14, 2000)
- Acceptance testing report: #АТНЛ 0.009.2081 (August 21, 2000)
- Toxicological and sanitary-chemical testing: #63-2000 (February 17, 2000) — confirming material safety
Trial Design and Assessment Areas
The trials were conducted in an outpatient environment. Assessment included:
- Patient tolerance of the applicators
- Character of the overall effect (normalizing vs. adverse)
- Safety and efficiency for normalizing functional state
- Usability properties
Initial assessments used biopotentiography of the small intestine in the infrared frequency range (0.12–0.27 Hz) as the primary functional measurement at Stage 1.
Significance
This document represents formal Russian Ministry of Public Health engagement with Aires technology — an important regulatory milestone. The authorization for clinical trials of a novel product by the Ministry's Committee on New Medical Equipment required meeting safety (toxicological), technical (acceptance testing), and scientific (expert commission) thresholds. The 2000 protocol represents the earliest documented point at which Aires technology received official regulatory recognition in Russia.